Journal Mobile Options
Table of Contents
Vol. 29, No. 6, 2009
Issue release date: June 2009
Am J Nephrol 2009;29:538–550
(DOI:10.1159/000191467)

Angiotensin II Upregulates RAGE Expression on Podocytes: Role of AT2 Receptors

Rüster C. · Bondeva T. · Franke S. · Tanaka N. · Yamamoto H. · Wolf G.
aKlinik für Innere Medizin III, Friedrich Schiller University, Jena, Germany; bDepartment of Biochemistry and Molecular Vascular Biology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, and cDepartment of Ophthalmology, Kyorin University School of Medicine, Kyorin, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Advanced glycation end products (AGEs) play an important role in diabetic nephropathy. The receptor for AGEs, called RAGE, is present on podocytes. We investigated whether angiotensin II (ANG II) modulates RAGE expression on cultured differentiated podocytes. Results: Cultured podocytes expressed AT1 and AT2 receptors. Surprisingly, ANG II induced RAGE mRNA and protein expression through AT2 receptors. ANG II had no influence on proliferation or protein content of podocytes. The increase in RAGE expression depended on stimulated transcriptional activity. Using various mutant reporter constructs of the RAGE promoter region, it was shown that a NF-κB binding site at –1519 was essential for ANG II-induced transcriptional activity. Preincubation with ANG II increased the expression of tumor necrosis factor-α mRNA and protein expression induced by AGE, indicating that the ANG II-mediated upregulation of RAGE has functional consequences. AGE-BSA was incorporated into cells as measured by Western blots for Nε-carboxymethyllysine, but ANG II did not influence this process. ANG II in the absence or presence of AGE-BSA did not induce apoptosis of podocytes. Conclusion: Our study revealed aninteraction between the renin-angiotensin system and the AGE/RAGE axis in podocytes. Since intraglomerular ANG II levels are increased in diabetic nephropathy, this interaction may have pathophysiological consequences for podocyte injury and inflammation associated with the development of diabetic nephropathy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rüster C, Wolf G: Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006;17:2985–2991.
  2. Wolf G, Butzmann U, Wenzel UO: The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003;93:P3–P13.
  3. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799–812.
  4. Schmidt AM, Yan SD, Wautier JL, Stern D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489–497.
  5. Wendt TM, Tanji N, Guo J, et al: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123–1137.
  6. Guo J, Ananthakrishnan R, Qu W, et al: RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 2008;19:961–972.
  7. Berbaum K, Shanmugam K, Stuchbury G, et al: Induction of novel cytokines and chemokines by advanced glycation end products determined with a cytometric bead array. Cytokine 2008;41:198–203.
  8. Siragy HM, Awad A, Abadir P, Webb R: The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 2003;144:2229–2233.
  9. Navarro JF, Milena FJ, Mora C, León C, et al: Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl 2005;99:S98–S102.
  10. Yamauchi K, Takano Y, Kasai A, et al: Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int 2006;70:892–900.
  11. Mundel P, Reiser J, Zuniga MB et al: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997;236:248–258.
  12. Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: past, present, and future. Kidney Int 2007;72:26–36.
  13. Rüster C, Bondeva T, Franke S, et al: Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 2008;23:2179–2191.
  14. Wolf G, Wenzel U, Burns KD, et al: Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors. Kidney Int 2002;61:1986–1995.
  15. Busch M, Franke S, Wolf G, et al: The advanced glycation end product Nε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 2006;48:571–579.
  16. Wolf G, Schanze A, Stahl RAK, et al: p27Kip1 knockout mice are protected from diabetic nephropathy: evidence for p27Kip1 haplotype insufficiency. Kidney Int 2005;68:1583–1589.
  17. Tanaka N, Yonekura H, Yamagishi S, et al: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781–25790.
  18. Liebau MC, Lang D, Böhm J, et al: Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006;290:F710–F719.
  19. Fujita M, Okuda H, Tsukamoto O, et al: Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:e138–e142.
  20. Yamagishi S, Takeuchi M, Matsui T, et al: Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 2005;57:4265–4270.

    External Resources

  21. Myint KM, Yamamoto Y, Doi T, et al: RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular-weight heparin. Diabetes 2006;55:2510–2522.
  22. Yamamoto Y, Kato I, Doi T, et al: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261–268.
  23. Tanji N, Markowitz GS, Fu C, et al: The expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. J Am Soc Nephrol 2000;11:1656–1666.
  24. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.
  25. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
  26. Gross ML, El-Shakmak A, Szabo A, et al: ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003;46:856–868.
  27. Durvasula RV, Petermann AT, Hiromura K, et al: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004;65:30–39.
  28. Yoo TH, Li JJ, Kim JJ, et al: Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007;71:1019–1027.
  29. Langham RG, Kelly DJ, Cox AJ, et al: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin-converting enzyme inhibition. Diabetologia 2002;45:1572–1576.
  30. Misfud SA, Allen TJ, Bertram JF, et al: Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001;44:878–882.
  31. Wang L, Flannery PJ, Spurney RF: Characterization of angiotensin II receptor subtypes in podocytes. J Lab Clin Med 2003;142:313–321.
  32. Wolf G, Ziyadeh FN, Thaiss F, et al: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997;100:1047–1058.
  33. Thomas MC, Tikellis C, Burns WM, et al: Interactions between renin-angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976–2984.
  34. Jia J, Ding G, Zhu J, et al: Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol 2008;28:500–507.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50